[Review] Outcomes and endpoints in cancer trials: bridging the divide
The Lancet Oncology
Cancer is not one disease. Outcomes and endpoints in trials should incorporate the therapeutic modality and cancer type because these factors affect clinician and patient expectations. In this Review, we discuss how to: define the importance of endpoints; make endpoints understandable to patients; improve the use of patient-reported outcomes; advance endpoints to parallel changes in trial design and therapeutic interventions; and integrate these improvements into trials and practice. Endpoints need to reflect benefit to patients, and show that changes in tumour size either in absolute terms (response and progression) or relative to control (progression) are clinically relevant.
Original Article: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70380-8/fulltext?rss=yes
No comments:
Post a Comment